References
- Saint-Laurent Thibault C, Moorjaney D, Ganz ML, et al. Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States. J Med Econ 2017:1-11. doi:10.1080/13696998.2017.1307204
- Centers for Disease Control and Prevention. U.S. 2011 surveillance data for viral hepatitis. Surveillance for viral hepatitis. Statistics and Surveillance; 2011. https://www.cdc.gov/hepatitis/statistics/2011surveillance/index.htm. [Last accessed May 12, 2017]
- Centers for Disease Control and Prevention. U.S. 2014 surveillance data for viral hepatitis. Surveillance for viral hepatitis. Statistics and Surveillance; 2014. https://www.cdc.gov/hepatitis/statistics/2014surveillance/index.htm. [Last accessed May 12, 2017]
- McGarry LJ, Pawar VS, Panchmatia HR, et al. Economic model of a birth cohort screening program for hepatitis C virus. Hepatology 2012;55:1344-55
- American Association for the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA). Retreatment of persons in whom prior therapy has failed. Recommendations for Testing, Managing, and Treating Hepatitis C. http://www.hcvguidelines.org/evaluate/monitoring. [Last accessed May 12, 2017]
- Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 2015;373:2608-17
- Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015;61:1127-35
- Dvory-Sobol H, Wyles D, Ouyang W, et al. Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir. J Hepatol 2015;62:S221
- Martin NK, Vickerman P, Miners A, et al. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology 2012;55:49-57
- Rein DB, Wittenborn JS, Smith BD, et al. The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus. Clin Infect Dis 2015;61:157-68
- Rein DB, Wittenborn JS, Weinbaum CM, et al. Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Dig Liver Dis 2011;43:66-72